Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data50
The role of patent analysis in target selection43
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)41
Malaria transmission blocking compounds: a patent review40
Update on mGlu4 modulator patents: 2017 to present37
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)35
FAK inhibitors in cancer, a patent review – an update on progress34
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities31
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)30
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)29
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review28
Caspase inhibitors: a review on recently patented compounds (2016–2023)28
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)27
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present26
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)26
A patent review of MAPK inhibitors (2018 – present)25
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)24
An updated patent review of AKT inhibitors (2020 – present)23
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review22
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)21
Antiprotozoal drugs: challenges and opportunities21
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)20
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
PDE1 inhibitors: a review of the recent patent literature (2008-present)17
Small-molecule RNA ligands: a patent review (2018–2024)17
Inhibition of GTPase KRAS G12D : a review of patent literature17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
A patent review of IDH1 inhibitors (2018-present)16
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature16
Dopamine D3 receptor ligands: a patent review (2014–2020)15
Antimalarial drugs: what’s new in the patents?15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
A patent and literature review of CDK12 inhibitors15
An updated patent review of MALT1 inhibitors (2021–present)15
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
Biofilm and bacterial membrane vesicles: recent advances13
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
A patent review of NLRP3 inhibitors to treat autoimmune diseases13
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
Sirtuin modulators: a review of patents from 2020 to 202413
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents12
An updated patent review of EZH2 inhibitors (2024–present)12
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)12
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
Are patents important indicators of innovation for Chagas disease treatment?12
The patent review of the biological activity of tropane containing compounds11
Correction11
An updated patent review of TRPA1 antagonists (2020 – present)11
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted11
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience11
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)11
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
A patent review of BRD4 inhibitors (2020–present)10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress10
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
0.22559118270874